“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting

Lafferty, Lise; Rance, Jake; Byrne, Marianne; Milat, Andrew; Dore, Gregory J.; Grebely, Jason; Lloyd, Andrew R.; Treloar, Carla

doi:10.1016/j.drugpo.2022.103746

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In literature, Canadian and US experiments showed that the implementation of point‐of‐care HCV screening was cost‐saving for PWIDs 36–38 …”

Section: Discussionmentioning

confidence: 99%

“…In literature, Canadian and US experiments showed that the implementation of point-of-care HCV screening was cost-saving for PWIDs. [36][37][38] Moreover, a recent state-transition model (STM) analysing the cost-utility of, respectively, the HCV point-of-care screening and the standard-of-care screening for PWIDs in Canada confirmed its medico-economic interest. 39 Finally, although we did not specifically make a comparative evaluation between the strategy on dedicated days and the standard daily care in our addictive care centers, the particularly high prevalence of HCV RNA-positive patients who could be treated in our experience argues in favour of the dedicated days.…”

Section: Profitability Of the Scanvir Conceptmentioning

confidence: 96%

See 1 more Smart Citation

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Debette-Gratien

François

Chevalier

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

According to the French recommendations, the elimination of the hepatitis C virus by 2025 could be a realistic public health goal. Screening policies are being intensified, and access to treatment is promoted for patients who escape the usual care pathway.The 'Scanvir' program is an original strategy based on dedicated screening days, as part of the 'test, treat and cure HCV' event in addiction care centers in a French region, during which innovative screening technologies (RDTs, FibroScan® and pointof-care HCV RNA testing) are brought on site and access to a multidisciplinary team is offered. A total of 392 patients attended the 67 regional Scanvir sessions: 31.6%were HCV Ab-positive and 66% of them were HCV RNA-positive. Treatment was initiated in 79.3% of the patients. RDTs were accepted by 62% of the PWIDs (including those who already knew their status) and FibroScan® by 99.5% of the patients. 80% of the viremic patients started their treatment on site and are now cured or still under treatment. Advanced fibrosis evaluated by FibroScan® (LSM > 8 KPa) was suspected in 13.4% and 14.1% of the global and the HCV population, respectively. Scanvir is an efficient strategy for HCV elimination based on dedicated days aimed at increasing cost-effectiveness and offering a multidisciplinary service while saving human care resources. It is an exportable strategy that also offers comprehensive screening of associated chronic liver diseases via the elastometry device and interviews.

show abstract

“…In literature, Canadian and US experiments showed that the implementation of point‐of‐care HCV screening was cost‐saving for PWIDs 36–38 …”

Section: Discussionmentioning

confidence: 99%

Section: Profitability Of the Scanvir Conceptmentioning

confidence: 96%

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Debette-Gratien

François

Chevalier

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…29,30 In the Australian SToP-C study, DAA treatment scale-up in prison settings significantly reduced HCV infection risk by nearly half-from 8.31 per 100 person-years to 4.35 per 100 person-years. 27,31 Modelling studies of HCV transmission trends in prisons across New South Wales suggested that scaling up treatment in prison environments could achieve similar HCV incidence reduction rates across the region, 32 with further reductions in HCV incidence when combined with access to harm reduction programs (e.g. prison needle and syringe programs, opioid agonist therapy).…”

Section: Petal A: Treatment As Preventionmentioning

confidence: 99%

“…Further, the HITS‐p study of PWID showed increased rates of sharing injecting equipment and decreased access to harm reduction programs among incarcerated PWID, resulting in onward HCV transmission in prisons 29,30 . In the Australian SToP‐C study, DAA treatment scale‐up in prison settings significantly reduced HCV infection risk by nearly half—from 8.31 per 100 person‐years to 4.35 per 100 person‐years 27,31 . Modelling studies of HCV transmission trends in prisons across New South Wales suggested that scaling up treatment in prison environments could achieve similar HCV incidence reduction rates across the region, 32 with further reductions in HCV incidence when combined with access to harm reduction programs (e.g.…”

Section: Leveraging Opportunities For Treatment and User Simplicity (...mentioning

confidence: 99%

Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs

Sulkowski,

Martinez,

Tyson

et al. 2024

Journal of Viral Hepatitis

View full text Add to dashboard Cite

All‐oral, direct‐acting antivirals can cure hepatitis C virus (HCV) in almost all infected individuals; yet, many individuals with chronic HCV are not treated, and the incidence of acute HCV is increasing in some countries, including the United States. Strains on healthcare resources during the COVID‐19 pandemic negatively impacted the progress toward the World Health Organization goal to eliminate HCV by 2030, especially among persons who inject drugs (PWID). Here, we present a holistic conceptual framework termed LOTUS (Leveraging Opportunities for Treatment/User Simplicity), designed to integrate the current HCV practice landscape and invigorate HCV treatment programs in the setting of endemic COVID‐19: (A) treatment as prevention (especially among PWID), (B) recognition that HCV cure may be achieved with variable adherence with evidence supporting some forgiveness for missed doses, (C) treatment of all persons with active HCV infection (viremic), regardless of acuity, (D) minimal monitoring (MinMon) during treatment, and (E) rapid test and treat (TnT). The objective of this article is to review the current literature supporting each LOTUS petal; identify remaining gaps in knowledge or data; define the remaining barriers facing healthcare providers; and review evidence‐based strategies for overcoming key barriers.

show abstract

Development of an evidence-based hepatitis C education program to enhance public health literacy in the Australian prison sector: The Hepatitis in Prisons Education program (HepPEd)

Sheehan,

Lafferty,

Tedla

et al. 2024

International Journal of Drug Policy

View full text Add to dashboard Cite

“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting

Cited by 3 publications

References 30 publications

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs

Development of an evidence-based hepatitis C education program to enhance public health literacy in the Australian prison sector: The Hepatitis in Prisons Education program (HepPEd)

Contact Info

Product

Resources

About